To investigate whether PD-1, PD-L1, and PD-L2 dynamics were associated with treatment efficacies, MDS patients were classified as HMA responders or HMA non-responders according to the IWG 2006 criteria (23). The gene discussed is PDCD1LG2; the disease is myelodysplastic syndrome.